CN-Trastuzumab

CN-Trastuzumab · Shanghai Institute Of Biological Products

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CN-Trastuzumab, covering 2023-12-27 to 2023-12-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer [Phase 3]